Prof. Dr. Meral Beksaç

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Bone Marrow Transplantation, 2022

DOI 10.1038/s41409-021-01560-y PMID 35013536 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

EXTRAMEDULLARY DISEASE

HemaSphere, 2022

DOI 10.1097/01.hs9.0000829504.35798.64 2 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Blood, 2022

DOI 10.1182/blood-2022-160004 2 citations (OpenAlex) Source : ORCID

Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA

Leukemia Research, 2022

DOI 10.1016/j.leukres.2022.106948 PMID 36108425 10 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Extramedullary disease in multiple myeloma: a systematic literature review

Blood Cancer Journal, 2022

DOI 10.1038/s41408-022-00643-3 PMID 35314675 239 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

First Experience of 11C-Methionine PET in Multiple Myeloma in Turkey

The Turkish Journal of Hematology, 2022

DOI 10.4274/tjh.galenos.2021.2020.0625 PMID 33355742 Texte intégral en libre accèsSource : ORCID

First Experience of11C-Methionine PET in Multiple Myeloma in Turkey,Multipl Myelomada11C-Metiyonin PET’in İlk Türkiye Deneyimi

Turkish Journal of Hematology, 2022

DOI 10.4274/tjh.galenos.2020.2020.0625 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID

Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study

American Journal of Hematology, 2022

DOI 10.1002/ajh.26536 PMID 35293006 9 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial

American Journal of Hematology, 2022

DOI 10.1002/ajh.26480 PMID 35089607 10 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial

EJHaem, 2022

DOI 10.1002/jha2.548 PMID 36467842 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?

Frontiers in Oncology, 2022

DOI 10.3389/fonc.2022.800711 PMID 35280810 5 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

Blood, 2022

DOI 10.1182/blood-2022-159710 6 citations (OpenAlex) Source : ORCID

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

The Lancet Oncology, 2022

DOI 10.1016/s1470-2045(22)00019-5 PMID 35151415 101 citations (Europe PMC) Source : ORCID

Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis

Clinical Lymphoma Myeloma and Leukemia, 2022

Source : ORCID

MM-086 Real-World Experience With Isatuximab (Isa) in Patients With Relapsed and/or Refractory Multiple Myeloma: IONA-MM First Interim Analysis

Clinical Lymphoma, Myeloma and Leukemia, 2022

DOI 10.1016/s2152-2650(22)01590-7 6 citations (OpenAlex) Source : ORCID

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab plus Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Blood, 2022

DOI 10.1182/blood-2022-159756 33 citations (OpenAlex) Source : ORCID

Manual Versus Automated Volume Reduction of Cord Blood

European Journal of Therapeutics, 2022

DOI 10.54614/eurjther.2021.0029 Texte intégral en libre accèsSource : ORCID

Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable

Clinical Lymphoma Myeloma and Leukemia, 2022

Source : ORCID

OPTIMISMM Subanalyse: Sicherheit von Pomalidomid (POM), Bortezomib (BORT) und Dexamethason (DEX) (PVd) Behandlung ( Tx) nach einer vorherigen Therapielinie (LoT) bei Patienten (pts) mit rezidiviertem oder refraktarem multiplen Myelom (RRMM)

Oncology Research and Treatment, 2022

Source : ORCID

Pomalidomide (POM), bortezomib (BORT), and dexamethasone (DEX) after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): a safety subanalysis of the phase 3 OPTIMISMM trial

Oncology Research and Treatment, 2022

Source : ORCID

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

European Journal of Haematology, 2022

DOI 10.1111/ejh.13706 PMID 34496096 10 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.8024 3 citations (OpenAlex) Source : ORCID

Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey

Clinical Lymphoma Myeloma and Leukemia, 2022

Source : ORCID

Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia

Clinical Lymphoma, Myeloma and Leukemia, 2022

DOI 10.1016/j.clml.2022.02.007 PMID 35410758 2 citations (Europe PMC) Source : ORCID

Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome

Bone Marrow Transplantation, 2022

Source : ORCID

Real-World Experience With Isatuximab (Isa) in Patients With Relapsed and/or Refractory Multiple Myeloma: IONA-MM First Interim Analysis

Clinical Lymphoma Myeloma and Leukemia, 2022

Source : ORCID

Real-world experience with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM): IONA-MM first interim analysis

Clinical Lymphoma Myeloma and Leukemia, 2022

Source : ORCID

Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

Blood, 2022

DOI 10.1182/blood-2022-170132 Source : ORCID

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Blood, 2022

DOI 10.1182/blood-2022-163483 14 citations (OpenAlex) Source : ORCID

The Impact of CD34+Cell and Immunefector Cell Dose on Transplant Outcomes

Blood, 2022

DOI 10.1182/blood-2022-155998 Source : ORCID

The efficacy and safety of second allogeneic hematopoietic stem cell transplantation

Journal of Clinical Oncology, 2022

Source : ORCID

Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019

British Journal of Haematology, 2022

DOI 10.1111/bjh.18025 PMID 35166376 13 citations (Europe PMC) Source : ORCID

İkinci Allojenik Kök Hücre Nakli: Gerçek Yaşam Verisi

LLM Dergi, 2022

DOI 10.5578/llm.20229804 Texte intégral en libre accèsSource : ORCID

P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL

HemaSphere, 2022

DOI 10.1097/01.hs9.0000829588.31575.a9 7 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT

HemaSphere, 2022

DOI 10.1097/01.hs9.0000846696.43332.f6 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY

HemaSphere, 2022

DOI 10.1097/01.hs9.0000846476.91419.a1 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Impfempfehlungen beim Multiplen Myelom: ein Konsensbericht des European Myeloma Network

Kompass Onkologie, 2022

DOI 10.1159/000522451 Source : OpenAlex

Is It Safe to Continue Allogeneic Hematopoietic Cell Transplantation Via Cryopreservation during COVID-19 Pandemic?

Transplantation and Cellular Therapy, 2022

DOI 10.1016/s2666-6367(22)00500-0 Texte intégral en libre accèsSource : OpenAlex

P28: RESPONSE AND VACCINATION STATUS OR LACK OF IMMUNOPARESIS ARE ASSOCIATED WITH BETTER OUTCOME FOLLOWING COVID-19 INFECTION AMONG PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE ON 110 PATIENTS

HemaSphere, 2022

DOI 10.1097/01.hs9.0000829684.63064.c2 Texte intégral en libre accèsSource : OpenAlex

P-258: Real-world experience with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM): IONA-MM first interim analysis

Clinical Lymphoma Myeloma & Leukemia, 2022

DOI 10.1016/s2152-2650(22)00588-2 Source : OpenAlex

P-099: Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable

Clinical Lymphoma Myeloma & Leukemia, 2022

DOI 10.1016/s2152-2650(22)00429-3 Source : OpenAlex

P-277: Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma

Clinical Lymphoma Myeloma & Leukemia, 2022

DOI 10.1016/s2152-2650(22)00607-3 Source : OpenAlex

Poster: MM-086 Real-World Experience With Isatuximab (Isa) in Patients With Relapsed and/or Refractory Multiple Myeloma: IONA-MM First Interim Analysis

Clinical Lymphoma Myeloma & Leukemia, 2022

DOI 10.1016/s2152-2650(22)01094-1 Source : OpenAlex

Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

Turkish Journal of Hematology, 2021

DOI 10.4274/tjh.galenos.2021.2021.0287 PMID 34521187 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Significance of inhibitory maternal killer-cell immunoglobulin-like receptor (KIR) and fetal KIR ligand genotype combinations in placenta related obstetric complications

Journal of Reproductive Immunology, 2021

DOI 10.1016/j.jri.2021.103425 PMID 34607283 4 citations (Europe PMC) Source : OpenAlex

The Efficacy of Therapeutic Thrombocytapheresis in Patients with Thrombocytosis

Journal of Ankara University Faculty of Medicine, 2021

DOI 10.4274/atfm.galenos.2021.08860 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID

The Influence of ATG on the Outcomes of Patients With AML at the Time of Unrelated Donor Transplantation

Journal of Ankara University Faculty of Medicine, 2021

DOI 10.4274/atfm.galenos.2021.95866 Texte intégral en libre accèsSource : ORCID

A Bottom-Up Proteomic Approach in Bone Marrow Plasma Cells of Newly Diagnosed Multiple Myeloma Patients

Current Proteomics, 2021

DOI 10.2174/1570164617999201124142232 Source : ORCID

A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

Blood, 2021

DOI 10.1182/blood-2021-147001 4 citations (OpenAlex) Source : ORCID

A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity

Immunogenetics, 2021

DOI 10.1007/s00251-021-01227-4 PMID 34536086 4 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID